A5060233994- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Tracheal and airway disorders
- Click Chemistry and Applications
- Cancer Cells and Metastasis
- Medical and Health Sciences Research
- Viral-associated cancers and disorders
- Urinary and Genital Oncology Studies
- Breast Lesions and Carcinomas
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac tumors and thrombi
- Aortic Thrombus and Embolism
- MRI in cancer diagnosis
- Bladder and Urothelial Cancer Treatments
Cancer Clinic
2025
NSABP Foundation
2025
National Cancer Institute
2025
National Center for Tumor Diseases
2025
Helios Hospital Berlin-Buch
2025
Evangelische Kliniken Gelsenkirchen
2016-2023
German Breast group
2018
Breast Center
2017
Evangelisches Krankenhaus Oberhausen
2009
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
BackgroundPatients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis KATHERINE, phase 3, open-label trial, showed that the or death was 50% lower adjuvant trastuzumab emtansine (T-DM1) than alone.MethodsWe randomly assigned patients HER2-positive in axilla treatment taxane-based chemotherapy to receive T-DM1 for 14 cycles. Here, we report...
503 Background: Optimal use of de-escalated, particularly chemotherapy(CT)-free, neoadjuvant regimens in HER2+ early breast cancer (EBC) is currently unclear as there are limited survival data so far. In ADAPT-HR-/HER2+, we previously showed an excellent pCR rate 90% after 12-week paclitaxel (Pac) +pertuzumab (P) +trastuzumab (T) and a substantial clinically meaningful 34% P+T alone HR-/HER2+ EBC. Here, present first data. Methods: The prospective multicenter WSG-ADAPT-HR-/HER2+ phase...
Background The phase 3 KATHERINE trial demonstrated significantly improved invasive disease–free survival with adjuvant trastuzumab emtansine (T‐DM1) versus in patients HER2‐positive early breast cancer and residual disease after neoadjuvant chemotherapy plus HER2‐targeted therapy. Methods Patients who received taxane‐ trastuzumab‐containing therapy (with/without anthracyclines) had (breast and/or axillary nodes) at surgery were randomly assigned to 14 cycles of T‐DM1 (3.6 mg/kg...
518 Background: In HER2+ EBC pCR rates after neoadjuvant chemo (CT)+/- anti-HER2 therapy differ according to hormone receptor (HR) status. The ADAPT HER2+/HR- phase II trial aims identify early responders (at 3 weeks) and evaluates the impact of additional paclitaxel (Pac) on in patients receiving dual blockade with trastuzumab + pertuzumab (T+P). Methods: 134 HER2+/HR-, cT1-4c, cN0/+ were randomized (2.5:1) 12 weeks T+P ± weekly Pac (2/14-12/15). After surgery, standard (CT+T) was...
Abstract #78 Background: Taxane based adjuvant chemotherapy (CHT) is standard of care in node-positive breast cancer. Several pre-planned subgroup analyses detected the maximum benefit from taxanes patients with 1-3 positive lymph nodes (LN).
 According to St. Gallen consensus CHT endocrine responsive tumors optional these patients. Recently ABCSG reported excellent survival data after therapy +/- bisphosphonates without low intermediate risk cancer (Gnant et al., ASCO 2008). The...
Abstract Background: In HR+/HER2- N0 early breast cancer (EBC), patients (pts) with Recurrence Score™ (RS)<26 (postmenopausal) and <16 (premenopausal) have excellent prognosis do not benefit fromadditional chemotherapy. However, prognostic impact of RS in N+ disease importance Ki67response after short preoperative endocrine therapy (ET) the context genomic signatures remainunclear. For first time, we present survival results from large prospective phase III WSG-ADAPTHR+/HER-...
We evaluated the role of early response after 3 weeks neoadjuvant treatment (NAT) assessed by ultrasound (US), magnetic resonance imaging (MRI) and Ki-67 dynamics for prediction pathologic complete (pCR) in different breast cancer subtypes. Patients with HR+/HER2+, HR-/HER2- HR-/HER2+ tumors enrolled into three WSG ADAPT subtrials underwent US, MRI assessment at diagnosis NAT. Early was defined as or partial (US, MRI) ≥30% proliferation decrease <500 invasive tumor cells (Ki-67). Predictive...
Abstract Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n 42). Gene expression analyzed baseline biopsies using NanoString Breast Cancer 360 panel 117); on-treatment...
515 Background: Taxanes and anthracyclines are the most active drugs in breast cancer. Taxane-based adjuvant chemotherapy is considered as standard node-positive cancer, though a large body of evidence derives from trials testing taxanes versus weak (4xAC). Subgroup analyses several indicate that patients with 1 to 3 positive nodes, at intermediate risk, will have maximum benefit taxane-based therapy. Methods: 2,011 primary cancer lymph nodes were randomized 3/2000 8/2005 phase III trial...
513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts residual disease after neoadjuvant chemotherapy plus HER2-targeted therapy. PROs are reported here. Methods: Eligible had HER2-positive early breast cancer, received taxane- and H-containing therapy (with/without anthracyclines) followed surgery, the and/or axillary nodes. Pts were randomized 14...
<p>CONSORT diagram</p>
<div>AbstractPurpose:<p>To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> trial (NCT01817452).</p>Experimental Design:<p>Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, <i>n</i> = 92) or P+T+paclitaxel...
<p>Supplementary Figure 2 shows association between RNA signatures and ypT0/is ypN0</p>
<p>Supplementary Figure 3 shows association between RNA signatures and overall survival</p>